ProCE Banner Activity

How I Interpret Clinical Trial Results to Choose Salvage Immunotherapies for Adult Patients With B-Precursor ALL

Clinical Thought
Are you ready to use immunotherapies for your patients with relapsed/refractory ALL? Dan Douer, MD, provides his interpretation of the data and discusses the benefits and risks of different treatments.

Released: September 01, 2016

Expiration: August 31, 2017

Share

Faculty

Dan Douer

Dan Douer, MD

Associate Professor of Medicine-Hematology
University of Southern California/Norris
Comprehensive Cancer Center and Hospital
Los Angeles, California

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational donation from

Amgen, Inc.

Faculty Disclosure

Primary Author

Dan Douer, MD

Associate Professor of Medicine-Hematology
University of Southern California/Norris
Comprehensive Cancer Center and Hospital
Los Angeles, California

Dan Douer, MD, has disclosed that he has received consulting fees from Amgen, Baxalta, Gilead Sciences, Jazz, Pfizer, and Spectrum; fees for non-CME/CE services from Baxalta and Jazz; and funds for research support from Baxalta, Bristol-Myers Squibb, Gilead Sciences, and Jazz.